Login
Home
Charts
Search
Watchlist
Products

Prevest Denpro Ltd

PREVEST·BSE
377.20-0.47%Tue, 22 Sept '26

Prevest Denpro Ltd

PREVEST
BSE
377.20
-0.47%
|Tue, 22 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
453Cr
Close
Close Price
377.00
Industry
Industry
Medical Equipment
PE
Price To Earnings
20.83
PS
Price To Sales
6.02
Revenue
Revenue
75Cr
Rev Gr TTM
Revenue Growth TTM
14.78%
PAT Gr TTM
PAT Growth TTM
14.92%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
131416131615181619181919
Growth YoY
Revenue Growth YoY%
-0.223.49.813.618.014.623.52.720.9
Expenses
ExpensesCr
991091010121012131212
Operating Profit
Operating ProfitCr
446565757677
OPM
OPM%
33.532.837.033.835.734.935.533.735.831.436.535.5
Other Income
Other IncomeCr
111111111111
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000001111
PBT
PBTCr
556566767688
Tax
TaxCr
112121222222
PAT
PATCr
445455546566
Growth YoY
PAT Growth YoY%
-10.132.424.47.820.214.94.213.227.9
NPM
NPM%
27.626.729.427.529.630.327.928.029.725.630.729.6
EPS
EPS
3.03.04.03.14.03.84.33.74.63.94.84.7
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
131416131615181619181919
Growth YoY
Revenue Growth YoY%
-0.223.49.813.618.014.623.52.720.9
Expenses
ExpensesCr
991091010121012131212
Operating Profit
Operating ProfitCr
446565757677
OPM
OPM%
33.532.837.033.835.734.935.533.735.831.436.535.5
Other Income
Other IncomeCr
111111111111
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000001111
PBT
PBTCr
556566767688
Tax
TaxCr
112121222222
PAT
PATCr
445455546566
Growth YoY
PAT Growth YoY%
-10.132.424.47.820.214.94.213.227.9
NPM
NPM%
27.626.729.427.529.630.327.928.029.725.630.729.6
EPS
EPS
3.03.04.03.14.03.84.33.74.63.94.84.7

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
56637275
Growth
Revenue Growth%
11.713.914.8
Expenses
ExpensesCr
37414749
Operating Profit
Operating ProfitCr
20222526
OPM
OPM%
35.235.034.434.8
Other Income
Other IncomeCr
3455
Interest Expense
Interest ExpenseCr
0000
Depreciation
DepreciationCr
1222
PBT
PBTCr
21242829
Tax
TaxCr
5677
PAT
PATCr
16182022
Growth
PAT Growth%
12.512.914.9
NPM
NPM%
28.628.828.528.9
EPS
EPS
13.415.117.118.1
Financial YearMar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
56637275
Growth
Revenue Growth%
11.713.914.8
Expenses
ExpensesCr
37414749
Operating Profit
Operating ProfitCr
20222526
OPM
OPM%
35.235.034.434.8
Other Income
Other IncomeCr
3455
Interest Expense
Interest ExpenseCr
0000
Depreciation
DepreciationCr
1222
PBT
PBTCr
21242829
Tax
TaxCr
5677
PAT
PATCr
16182022
Growth
PAT Growth%
12.512.914.9
NPM
NPM%
28.628.828.528.9
EPS
EPS
13.415.117.118.1

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
121212
Reserves
ReservesCr
7794113
Current Liabilities
Current LiabilitiesCr
667
Non Current Liabilities
Non Current LiabilitiesCr
111
Total Liabilities
Total LiabilitiesCr
95113133
Current Assets
Current AssetsCr
6886106
Non Current Assets
Non Current AssetsCr
272727
Total Assets
Total AssetsCr
95113133
Financial YearMar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
121212
Reserves
ReservesCr
7794113
Current Liabilities
Current LiabilitiesCr
667
Non Current Liabilities
Non Current LiabilitiesCr
111
Total Liabilities
Total LiabilitiesCr
95113133
Current Assets
Current AssetsCr
6886106
Non Current Assets
Non Current AssetsCr
272727
Total Assets
Total AssetsCr
95113133

Cash Flow

Consolidated
Standalone
Financial YearMar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
121515
Investing Cash Flow
Investing Cash FlowCr
-2-1-2
Financing Cash Flow
Financing Cash FlowCr
0-1-1
Net Cash Flow
Net Cash FlowCr
101212
Free Cash Flow
Free Cash FlowCr
81313
CFO To PAT
CFO To PAT%
72.081.672.3
CFO To EBITDA
CFO To EBITDA%
58.667.159.9
Financial YearMar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
121515
Investing Cash Flow
Investing Cash FlowCr
-2-1-2
Financing Cash Flow
Financing Cash FlowCr
0-1-1
Net Cash Flow
Net Cash FlowCr
101212
Free Cash Flow
Free Cash FlowCr
81313
CFO To PAT
CFO To PAT%
72.081.672.3
CFO To EBITDA
CFO To EBITDA%
58.667.159.9

Ratios

Consolidated
Standalone
Financial YearMar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
424514410453
Price To Earnings
Price To Earnings
26.328.320.020.8
Price To Sales
Price To Sales
7.27.95.56.0
Price To Book
Price To Book
4.84.93.33.6
EV To EBITDA
EV To EBITDA
18.920.513.714.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
68.269.370.770.7
OPM
OPM%
35.235.034.434.8
NPM
NPM%
28.628.828.528.9
ROCE
ROCE%
24.223.022.122.1
ROE
ROE%
18.217.216.416.4
ROA
ROA%
17.016.115.415.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
424514410453
Price To Earnings
Price To Earnings
26.328.320.020.8
Price To Sales
Price To Sales
7.27.95.56.0
Price To Book
Price To Book
4.84.93.33.6
EV To EBITDA
EV To EBITDA
18.920.513.714.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
68.269.370.770.7
OPM
OPM%
35.235.034.434.8
NPM
NPM%
28.628.828.528.9
ROCE
ROCE%
24.223.022.122.1
ROE
ROE%
18.217.216.416.4
ROA
ROA%
17.016.115.415.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Prevest Denpro is a dental-materials manufacturer that started in a 200-square-foot room in Jammu in 1999 and now sells to over 90 countries from a 60,000-square-foot factory - one of the few companies in India that actually makes these products rather than repackaging someone else’s. The business was built by the Modi family and has stayed debt-free while expanding from basic consumables into digital dentistry, biomaterials, and oral-care brands, all developed through an in-house R&D lab that the government recognises as a research centre. The recurring approach is simple: make products that match multinational quality, sell them at a lower price because manufacturing costs in Jammu are lower, and keep adding categories so a dentist can fill most of their clinical needs from one catalogue. # Business segments A single manufacturing-and-R&D engine that expresses itself through five product verticals - dental consumables, digital dentistry, endodontic systems, disinfectants, and a consumer oral-care brand - all built on the same factory, the same research lab, and the same distributor network. ## 1. Dental consumables: the catalogue that pays for everything else **Over 100 products across 12 clinical categories, sold through distributors in 90-plus countries, generate the core revenue that funds every newer vertical.** - **One factory, one shift, plenty of room** - the Jammu plant has an installed capacity of 200 metric tonnes a year but was running at only about 45% utilisation as of FY24, so the company can grow volumes without building a new factory. - **A product for almost every chairside need** - the 12 categories span root-canal sealers, filling composites, cements, impression materials, whitening gels, and temporary crown materials, meaning a single sales call can cover most of a clinic’s recurring purchases. - **Regulatory approvals open doors** - the company holds USFDA clearance for over 20 products, plus ISO 13485, CE, Saudi FDA, and MDSAP certifications covering the US, Canada, and Brazil, so it can sell into regulated markets that many smaller Indian competitors cannot reach. - **Export-first economics** - roughly 60% of revenue comes from exports, where pricing and value addition are better than in India’s price-sensitive domestic market; Asia and Africa together account for about 70% of geographic revenue, with Europe at roughly 20%. - **Training creates loyalty** - the company runs continuing-education programmes for dentists and has tie-ups with 12 dental colleges, so clinicians learn on Prevest products and tend to reorder what they know. ## 2. Digital dentistry: the highest-priority bet on the future **A developing ecosystem of 3D-printing resins, in-house LCD printers, and intraoral scanners that management calls its most important growth segment.** - **Resins first, hardware next** - the company already sells dental-grade 3D-printing resins for crowns, bridges, inlays, onlays, and veneers, and is now designing its own LCD-based 3D printers using sourced components, aiming for an integrated printer-plus-resin system. - **Chasing a fast-growing market** - the global digital-dentistry market was valued at about $6.8 billion in 2025 and is projected to reach $17.9 billion by 2033, with Asia-Pacific expected to grow fastest, so the company is building capacity into a rising tide. - **USFDA registration underway** - the company has completed formalities to register its 3D resins with the USFDA, which would unlock the large North American market where digital workflows are already mainstream. ## 3. Endodontic systems: the file that drills into a niche **A range of nickel-titanium rotary files for root-canal shaping, anchored by the Rotoflex brand, that turns a consumable into a system sale.** - **Repeat demand validates the product** - the Rotoflex endodontic file system has seen increasing reorders from clinicians, which in a procedure-driven category signals that the files perform reliably in real clinical use. - **Backed by specialist society ties** - the company has partnered with the Indian Endodontic Society for education and research, giving the brand credibility with the specialists who influence file adoption. ## 4. Disinfectants and hygiene: a new vertical in a new building **Infection-control products for dental and medical settings, manufactured in a dedicated 16,000-square-foot facility commissioned alongside the main plant.** - **Built for a post-pandemic need** - the product line includes surface disinfectants, wipes, and hand-hygiene solutions under the ViroZym and ViroShield labels, targeting the same dental clinics and hospitals that already buy the company’s consumables. - **Early demand is encouraging** - initial customer response after the FY26 launch has been strong, though the vertical is still ramping up and was delayed earlier by regulatory clearances. ## 5. Oradox oral care: the consumer shelf experiment **A branded range of toothpastes, mouthwashes, and oral-care gels that takes the company beyond the dental clinic and into retail.** - **Same science, different buyer** - the Oradox line leverages the company’s formulation know-how but targets consumers rather than dentists, representing a B2C channel alongside the core B2B business. - **Still a seedling** - as of FY25, the brand had not yet made a meaningful revenue contribution, so it remains an early-stage initiative within the broader portfolio. # Group structure and partners **A debt-free promoter-led company with three young subsidiaries - one for marketing in India, one for US market entry, and one for the Middle East - plus research partnerships that feed the product pipeline.** - **Denvisio Biomed Limited** - incorporated in May 2023 and based in Gurugram, this wholly owned subsidiary handles marketing, digital campaigns, and brand-building for both domestic and international markets, freeing the parent to focus on manufacturing and R&D. - **Axiodent (USA)** - a Delaware subsidiary set up in February 2025 to manage FDA registrations, local distribution, customer service, and brand visibility at US dental events; it has already begun contributing with initial orders and private-label work. - **Prevest Denpro Gulf (UAE)** - a wholly owned subsidiary established in 2025 to strengthen Middle East presence, though commercial operations were delayed by regional geopolitical tensions; the board approved up to AED 500,000 in investment in May 2026. - **Research partnerships with teeth** - a five-year MoU with the Indian Dental Association covers clinical education; separate agreements with IIT Kanpur (biomaterials for dental and orthopaedic use) and Sree Chitra Tirunal Institute (bioactive bone cement) give the company access to institutional science it does not have to build from scratch.

Documents — Prevest Denpro Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/pmfx6rguul718bnaofx2lur3.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/rveyr2cuvv3ynoouvdu9zu8o.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/tawq3xsvqgb8s6mb0sg054f2.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/6ikkui1zacoqh6g7pyh791wt.pdf
  • Q4 FY2024 Earnings Call Transcript (Mar 2024, PDF): https://www.stockscans.in/document/9uexjpfwj9132pkyepvgx3vb.pdf
  • Q3 FY2024 Earnings Call Transcript (Dec 2023, PDF): https://www.stockscans.in/document/i627lwi3mdo3lxi0dhx47krj.pdf
  • Q2 FY2024 Earnings Call Transcript (Sep 2023, PDF): https://www.stockscans.in/document/f7n2n20x3nh5g22wtfmkjl4d.pdf
  • Q1 FY2024 Earnings Call Transcript (Jun 2023, PDF): https://www.stockscans.in/document/251q8wzluzj8z2a1bnn0zxe8.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/8zecfdw3apy4e3urar614cqg.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/mcauybr4j8zz893r21itip5x.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/x221tbnru0kpfz6hg8v9qcyw.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/jj1b9u4ji6twz5rsgstjxmem.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/547lert1vr1i79zjr2avibjr.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/0g791j6g2bc1j1ppr77qatt9.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/b07u7d2rp0oa2g1i7aigl208.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/3s2oivahsht52yw7jxpcs3bu.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/d81tu99zmqfz34vbtx6jsja6.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/os5xrkhe2d9wqjbsc0skgnse.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/870qscrx0nn16awsw1shv1og.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/xirmxipy60glp4v7ka317daw.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/6s2q91653n5zum5al2j16del.pdf
  • Q1 FY2025 Investor Presentation (Jun 2024, PDF): https://www.stockscans.in/document/8fv281y9midaayhfl8adzibf.pdf
  • Q4 FY2024 Investor Presentation (Mar 2024, PDF): https://www.stockscans.in/document/y1bolprefos0idbnxbeeywuk.pdf
  • Q3 FY2024 Investor Presentation (Dec 2023, PDF): https://www.stockscans.in/document/bg7qqqfz6kr0boxogoali4v9.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/nuvmofqjpez7rp8tvh9z5p7a.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/v1nrlf4ixzzy6gq8p0a70wqv.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/sxmcpzjsiaizltpet4k2kpaf.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/si7dpoa0gve7ow0k4t07b93c.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/j4sp1lku0kl16eo4nuux4i79.pdf

Concall Transcript Summaries — Prevest Denpro Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/BSE%3APREVEST/transcript-notes/202606/pmfx6rguul718bnaofx2lur3.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/BSE%3APREVEST/transcript-notes/202509/rveyr2cuvv3ynoouvdu9zu8o.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/BSE%3APREVEST/transcript-notes/202503/tawq3xsvqgb8s6mb0sg054f2.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/BSE%3APREVEST/transcript-notes/202409/6ikkui1zacoqh6g7pyh791wt.pdf
  • Q4 FY2024 Concall Transcript Summary (Mar 2024): https://www.stockscans.in/company/BSE%3APREVEST/transcript-notes/202403/9uexjpfwj9132pkyepvgx3vb.pdf
  • Q3 FY2024 Concall Transcript Summary (Dec 2023): https://www.stockscans.in/company/BSE%3APREVEST/transcript-notes/202312/i627lwi3mdo3lxi0dhx47krj.pdf
  • Q2 FY2024 Concall Transcript Summary (Sep 2023): https://www.stockscans.in/company/BSE%3APREVEST/transcript-notes/202309/f7n2n20x3nh5g22wtfmkjl4d.pdf
  • Q1 FY2024 Concall Transcript Summary (Jun 2023): https://www.stockscans.in/company/BSE%3APREVEST/transcript-notes/202306/251q8wzluzj8z2a1bnn0zxe8.pdf